Cancer最新文献

{"title":"Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement","authors":"Udhayvir S. Grewal MD,&nbsp;Po H. Ear PhD,&nbsp;Mohamad B. Sonbol MD,&nbsp;Andrew M. Bellizzi MD,&nbsp;Johannes Hofland MD,&nbsp;Joakim Crona MD, PhD,&nbsp;Joseph S. Dillon MD,&nbsp;Jennifer A. Chan MD,&nbsp;James R. Howe MD,&nbsp;Jonathan Strosberg MD,&nbsp;Simron Singh MD,&nbsp;Thorvardur R. Halfdanarson MD","doi":"10.1002/cncr.70586","DOIUrl":"10.1002/cncr.70586","url":null,"abstract":"<p>Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RA) and dual incretin agonists, are increasingly used for the management of diabetes, obesity, and cardiometabolic disease. Although their systemic benefits are well established, uncertainty remains regarding their safety in patients with neuroendocrine neoplasms (NENs), a biologically heterogeneous group of tumors with diverse molecular profiles. Preclinical studies suggest that GLP-1 receptor activation may promote tumor growth in select receptor-expressing models, although receptor expression varies widely across NEN subtypes and is often absent in common tumors such as ileal neuroendocrine tumors. Population-level and retrospective clinical data have not demonstrated a consistent increase in oncologic risk but are limited by methodological constraints. In this expert consensus statement, the authors synthesize current evidence and provide a practical framework for the use of incretin mimetics in patients with NENs. The authors emphasize individualized risk assessment, shared decision-making, and multi-disciplinary collaboration, balancing potential but unquantified oncologic risks against substantial cardiometabolic benefits. Until prospective data are available, careful patient selection, dose optimization, and close clinical and radiologic surveillance remain essential to guide safe and effective use of these agents in this population.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148756878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo T-cell depletion and pharmacokinetic-based busulfan conditioning regimen improve the outcomes in acute myeloid leukemia (AML) in complete remission undergoing to allogeneic stem cell transplantation","authors":"Roberto Bono MD,&nbsp;Cristina Rotolo MD,&nbsp;Giuseppe Sapienza MD,&nbsp;Corinne Spoto MD,&nbsp;Carmelo Costanza Ph,&nbsp;Sergio Indelicato Ph,&nbsp;Caterina Patti MD,&nbsp;Antonino Mulè MD,&nbsp;Valeria Calafiore MD,&nbsp;Giulia Arrigo MD,&nbsp;Alessandra Santoro Ph,&nbsp;Laura Di Noto MD,&nbsp;Luca Castagna MD","doi":"10.1002/cncr.70545","DOIUrl":"https://doi.org/10.1002/cncr.70545","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148753935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of real-world clinical outcomes of perioperative chemotherapy compared to preoperative chemoradiotherapy in esophagogastric adenocarcinoma","authors":"Mosunmoluwa Oyenuga MD, MPH,&nbsp;Subir Goyal PhD,&nbsp;Lindsay M. Hannan MD, MSc,&nbsp;Oluwadunni Emiloju MD, MS,&nbsp;Gideon T. Dosunmu MD, MPH,&nbsp;Ruoyu Miao MD, PhD,&nbsp;Olumide Gbolahan MD, MS,&nbsp;Maria Russell MD,&nbsp;Jolinta Lin MD,&nbsp;Jeffrey M. Switchenko PhD,&nbsp;Olatunji B. Alese MD","doi":"10.1002/cncr.70571","DOIUrl":"https://doi.org/10.1002/cncr.70571","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Nonmetastatic esophagogastric adenocarcinoma require multimodal treatment for management. However, real-world treatment patterns and outcomes in these patients are limited. We evaluated the survival outcomes associated with the common treatment combinations in the National Cancer Database.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 4715 patients met the predefined inclusion and exclusion criteria. Four groups were created: group 1, preoperative chemotherapy; group 2, perioperative chemotherapy; group 3, preoperative chemotherapy followed by chemoradiation; and group 4, preoperative chemoradiotherapy. Kaplan–Meier curves were used to assess overall survival. Cox proportional hazard regression estimated hazard ratios (HR) and 95% CIs for associations between covariates and overall survival. Inverse probability of treatment weighting based on propensity scores were used to account for differences in baseline characteristics between treatment groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The median age was 63 years; 75.9% were male and 82.9% were non-Hispanic White; overall, 47.5% had clinical stage III disease and 57.8% had regional lymph node involvement. Median follow-up was 79.5 months. Patients who received perioperative chemotherapy had improved median overall survival compared with patients who received preoperative chemoradiotherapy (79.1 vs 74.6 months; <i>p</i> &lt; .001). After adjustment for age, race, Charlson–Deyo Score, facility type, year of diagnosis, presence of regional lymph nodes, clinical stage, the association remained statistically significant (HR = 0.78; 95% CI, 0.66–0.92; <i>p</i> = .003).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although several multimodality treatment strategies are used for esophagogastric adenocarcinoma, perioperative chemotherapy is associated with better overall survival compared to preoperative chemoradiotherapy.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148753936","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Top advances of the year: Breast cancer.","authors":"Heather Gatcombe, Demetria Smith Graziani, Tyler Kristoff, Cletus Arciero, Kevin Kalinsky","doi":"10.1002/cncr.70572","DOIUrl":"10.1002/cncr.70572","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":"e70572"},"PeriodicalIF":5.6,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13479787/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical outcomes associated with NPM1 mutations in newly diagnosed acute myeloid leukemia","authors":"Aziz Farhat MD,&nbsp;Georgina El Hajjar MD,&nbsp;Hagop Kantarjian MD,&nbsp;Koji Sasaki MD, PhD,&nbsp;Nicholas J. Short MD,&nbsp;Branko Cuglievan MD,&nbsp;Sanam Loghavi MD,&nbsp;Keyur Patel MD, PhD,&nbsp;Alex Bataller MD, PhD,&nbsp;Wei Ying Jen MA, BMBCh, MRCP, MMed, FRCPath,&nbsp;Musa Yilmaz MD,&nbsp;Guillermo Montalban-Bravo MD,&nbsp;Danielle Hammond MD,&nbsp;Naveen Pemmaraju MD,&nbsp;Naval Daver MD,&nbsp;Farhad Ravandi MD,&nbsp;Elias Jabbour MD,&nbsp;Tapan Kadia MD,&nbsp;Gautam Borthakur MD,&nbsp;Guillermo Garcia-Manero MD,&nbsp;Courtney D. DiNardo MD,&nbsp;Ghayas C. Issa MD, MS","doi":"10.1002/cncr.70568","DOIUrl":"10.1002/cncr.70568","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Nucleophosmin 1-mutated (<i>NPM1mt</i>) acute myeloid leukemia (AML) is associated with a relatively favorable prognosis though long-term outcomes remain suboptimal without clear predictors identified by therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In a retrospective analysis, the authors identified 396 patients (18%) with newly diagnosed (ND) <i>NPM1mt</i> AML treated at The University of Texas MD Anderson Cancer Center and analyzed their outcomes. Using a Cox regression model, they analyzed predictors of survival in newly diagnosed <i>NPM1mt</i> AML across various therapies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Those treated with high intensity chemotherapy had a median overall survival (OS) of 84.7 months with a 5-year rate of 53% (95% CI, 44%–61%) whereas those treated with a combination of a hypomethylating agent (HMA) and venetoclax had a median OS of 23.3 months with a 5-year rate of 19% (95% CI, 5%–39%). The combination of cladribine, low-dose cytarabine, and venetoclax alternating with azacitidine and venetoclax yielded better survival compared with HMA and venetoclax in an age-matched analysis (5-year OS rate of 74% vs. 24%) (<i>p</i> = .048).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Among patients with <i>NPM1mt</i> treated with high-intensity chemotherapy, older age, a poor performance status, and presence of a <i>FLT3-ITD</i> mutation or extramedullary disease predicted a worse overall survival. For patients treated with a hypomethylating agent and venetoclax, older age was the only predictor of worse long-term outcomes. These findings can be used for risk-stratification of newly diagnosed <i>NPM1mt</i> AML and provide benchmarks of response and survival for this subtype.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70568","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort”","authors":"","doi":"10.1002/cncr.70508","DOIUrl":"10.1002/cncr.70508","url":null,"abstract":"<p>Martin TG, Mateos M-V, Yi JH, et al. Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: pooled findings from three clinical cohorts and a retrospective cohort. <i>Cancer</i>. 2026;e70237. doi:10.1002/cncr.70237</p><p>This correction is issued to address the following updates:</p><p>1. Figure 1C previously contained incorrect patient-at-risk numbers for overall survival (OS); the corrected Figure 1C is shown below.</p><p>2. Figure 2B previously contained incorrect patient-at-risk numbers for duration of response (DOR) and progression-free survival (PFS); the corrected Figure 2B is shown below.</p><p>We apologize for these errors.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70508","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Cancer incidence in the US military: An updated analysis”","authors":"","doi":"10.1002/cncr.70553","DOIUrl":"10.1002/cncr.70553","url":null,"abstract":"<p>Bytnar JA, McGlynn KA, Nealeigh MD, Shriver CD, Zhu K. Cancer incidence in the US military: an updated analysis. <i>Cancer</i>. 2024; 130(1): 96-106. doi:10.1002/cncr.34978</p><p>In the abstract section, the statement “Persons in ACTUR were active-duty members 20-59 years old during 1990-013.” was incorrect. This should have read: “Persons in ACTUR were active-duty members 20-59 years old during 1990-2013.”</p><p>The authors apologize for this error.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70553","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148710790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The American Cancer Society National Lung Cancer Roundtable strategic plan: Opportunities in advanced imaging across the lung cancer care continuum","authors":"Daniel C. Sullivan MD,&nbsp;Michael McNitt-Gray PhD,&nbsp;Denise R. Aberle MD,&nbsp;Ricardo S. Avila MS,&nbsp;Samuel G. Armato III PhD,&nbsp;Paul M. Bergstrom Jr PhD,&nbsp;Maria Chong MD,&nbsp;Dianna D. Cody PhD,&nbsp;Laura P. Coombs PhD,&nbsp;Richard A. Frank MD, PhD,&nbsp;Robert J. Gillies PhD,&nbsp;Jonathan G. Goldin MD, PhD,&nbsp;Jayashree Kalpathy-Cramer PhD,&nbsp;Paul E. Kinahan PhD,&nbsp;Matthew B. Schabath PhD,&nbsp;Robert A. Smith PhD,&nbsp;David F. Yankelevitz MD,&nbsp;Ella A. Kazerooni MD, MS","doi":"10.1002/cncr.70516","DOIUrl":"10.1002/cncr.70516","url":null,"abstract":"<p>Lung cancer is the leading cause of cancer death in men and women. The goal of reducing mortality from lung cancer requires improvements in many aspects of the care pathway, beginning with early detection. Advances in imaging technologies and their application in clinical practice can contribute to addressing these challenges. As part of the American Cancer Society National Lung Cancer Roundtable’s strategic plan, the roundtable’s Advanced Imaging Across the Lung Cancer Care Continuum Task Group identified four advanced imaging technology topics as priority areas for development. These include novel (1) imaging technologies, (2) quantitative imaging biomarkers, (3) systems for sharing image data and/or algorithms, and (4) imaging-related artificial intelligence solutions. The authors provide background for each priority topic, describe key clinical problems along the lung cancer care pathway as use-case scenarios, and comment on challenges that impede implementation and dissemination of these potential advances.</p>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70516","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148710842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Patient-reported outcomes and targeted therapeutic escalation in NRG Oncology/RTOG 1010: When intensification fails to translate to improved outcomes","authors":"Timothy J. Brown MD, MSCE,&nbsp;Nicholas J. Hornstein MD, PhD,&nbsp;Udhayvir S. Grewal MD,&nbsp;Nina N. Sanford MD","doi":"10.1002/cncr.70576","DOIUrl":"10.1002/cncr.70576","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148710859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disease-free survival as a surrogate outcome for localized kidney cancer—A systematic review and meta-analysis","authors":"Constanza Martinez MD, PhD,&nbsp;David Chen BMSc,&nbsp;Russell Leong BHSc,&nbsp;Nicholas Lum BHSc,&nbsp;Karren Xiao BHSc,&nbsp;Laith Almasri BSc,&nbsp;Christian K. Kollmannsberger MD,&nbsp;Srinivas Raman MD, MASc","doi":"10.1002/cncr.70567","DOIUrl":"10.1002/cncr.70567","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Disease-free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma (<i>R</i>CC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors conducted a systematic review and trial-level meta-analysis of randomized controlled trials assessing systemic or perioperative therapies in patients with localized RCC. Databases were searched from inception to June 10, 2025. Trial-level surrogacy between DFS and OS was assessed using weighted least-squares meta-regression of log-transformed hazard ratios (HRs), and the surrogate threshold effect was estimated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 25 randomized controlled trials were analyzed; 13 trials, analyzed as 15 study-level units comprising 9594 patients, reported HRs for both OS and DFS. DFS demonstrated a strong correlation with OS (weighted Pearson correlation coefficient, 0.75; 95% confidence level, 0.55–0.91; corresponding coefficient of determination, 0.57). The surrogate threshold effect analysis identified a DFS HR &lt;0.914 as predictive of OS benefit. Funnel plots showed no clear asymmetry, and Egger tests did not indicate significant publication bias.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>DFS demonstrated a strong association with OS and may serve as a valid trial-level surrogate end point patients with in localized RCC. A DFS HR &lt;0.914 was more likely to predict an OS benefit. These findings support the use of DFS as a primary end point in localized RCC trials, whereas continued long-term follow-up and future patient-level validation remain important.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"132 16","pages":""},"PeriodicalIF":5.6,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.70567","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148719793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}